Brigatinib

證據等級: L5

預測適應症: 10 個

Brigatinib: From ALK-Positive Non-Small Cell Lung Cancer to Gingival Fibromatosis

One-Sentence Summary

Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor, originally approved for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). The TxGNN model predicts it may be effective for Gingival Fibromatosis, however there are currently 0 clinical trials and 0 publications directly supporting this specific indication, placing this at the lowest evidence level (L5).

Quick Overview

Item	Content
Original Indication	ALK-positive metastatic non-small cell lung cancer (NSCLC)
Predicted New Indication	Fibromatosis, Gingival
TxGNN Prediction Score	99.89%
Evidence Level	L5 — Model prediction only, no actual studies
Malaysia Market Status	✓ Marketed
Number of Registrations	3
Recommended Decision	Hold

Why is This Prediction Reasonable?

Brigatinib (brand name ALUNBRIG™) is a next-generation small molecule tyrosine kinase inhibitor that primarily targets anaplastic lymphoma kinase (ALK). It also exhibits inhibitory activity against additional kinases including ROS1, FLT3, EGFR (including T790M mutant), and IGF-1R. It was first approved by the US FDA in April 2017 for ALK-positive metastatic NSCLC, and its first-line efficacy was established through the landmark Phase 3 ALTA-1L trial demonstrating superior progression-free survival over crizotinib. Detailed mechanism of action data was not available in the Evidence Pack, but based on extensive published literature, brigatinib’s primary mechanism involves potent and selective inhibition of ALK kinase activity, blocking downstream oncogenic signalling pathways (RAS/MAPK, PI3K/AKT, JAK/STAT).

Gingival fibromatosis is a benign condition characterised by progressive, non-neoplastic fibrous overgrowth of gingival tissue. It can be hereditary (caused by mutations in genes such as SOS1 or HGF) or drug-induced (commonly by calcium channel blockers, cyclosporin, or phenytoin). The pathophysiology involves excessive collagen deposition by gingival fibroblasts, driven by growth factor signalling (particularly TGF-β and CTGF pathways) rather than kinase-driven oncogenic proliferation.

The mechanistic link between ALK inhibition and gingival fibromatosis is weak. There is no established evidence that ALK signalling plays a role in gingival fibroblast proliferation or collagen overproduction. While TxGNN assigned a high prediction score (99.89%), this likely reflects topological proximity in the knowledge graph rather than a true pharmacological rationale. The absence of any clinical trials, case reports, or preclinical studies linking brigatinib (or any ALK inhibitor) to gingival fibromatosis further underscores the speculative nature of this prediction.

Clinical Trial Evidence

Currently no related clinical trials registered for brigatinib in gingival fibromatosis.

Literature Evidence

Currently no related literature available for brigatinib in gingival fibromatosis.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(Details pending)	—	—	ALK-positive NSCLC
(Details pending)	—	—	ALK-positive NSCLC
(Details pending)	—	—	ALK-positive NSCLC

Note: 3 registrations are recorded in the NPRA database, but detailed product information (authorization numbers, product names, dosage forms, and approved indication text) was not available in the current data extract.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (ALK tyrosine kinase inhibitor)
Myelosuppression Risk	Low to moderate — lymphopenia and anaemia reported; severe myelosuppression uncommon compared to conventional cytotoxics
Emetogenicity Classification	Low
Monitoring Items	CBC with differential, hepatic transaminases (ALT/AST), lipase/amylase, serum creatinine, blood glucose, blood pressure; pulmonary function (risk of early-onset pulmonary events/ILD)
Handling Protection	Standard precautions for oral antineoplastic agents; no cytotoxic spill kit required for intact tablets, but broken/crushed tablets should be handled with gloves per institutional guidelines

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available in the current evidence pack.

Known class-level safety signals from published literature include:

Interstitial lung disease (ILD) / Pneumonitis: Early-onset pulmonary events (within 7 days of initiation) reported in clinical trials; dose escalation strategy (90 mg × 7 days → 180 mg) was implemented to mitigate this risk
Hypertension: Treatment-emergent hypertension reported in ALTA-1L; blood pressure monitoring recommended
Hepatotoxicity: Elevations in ALT/AST observed; periodic liver function monitoring advised
Tumour lysis syndrome (TLS): A fatal case of brigatinib-induced TLS has been reported in the literature (PMID: 34987411)
Visual disturbances: Blurred vision and other visual symptoms reported

Additional Predicted Indications Overview

Given that the top-ranked prediction (gingival fibromatosis) lacks mechanistic rationale, a summary of all 10 predicted indications is provided below for completeness:

Rank	Predicted Indication	TxGNN Score	Evidence Level	Mechanistic Plausibility	Recommendation
1	Fibromatosis, gingival	99.89%	L5	None — no ALK pathway involvement	Hold
2	Fibroma of lung	99.86%	L5	None — benign tumour, no ALK activation	Hold
3	Hamartoma of lung	99.85%	L5	None — HMGA2-driven, not ALK	Hold
4	Lung hilum carcinoma	99.85%	L4	Conditional — if ALK+ NSCLC subtype, brigatinib already has Phase 3 evidence	Research Question
5	Lung benign neoplasm	99.85%	L5	None — benign tumours lack ALK activation	Hold
6	IBMPFD (VCP-related)	99.84%	L5	None — VCP gene mutation, unrelated to ALK	Hold
7	Lung germ cell tumour	99.84%	L4	Weak — ALK not a common driver in GCTs	Hold
8	Pulmonary sulcus neoplasm	99.84%	L4	Conditional — Pancoast tumour is NSCLC; if ALK+, existing evidence applies	Research Question
9	Junctional epidermolysis bullosa	99.83%	L5	None — structural protein defect, unrelated to kinase signalling	Hold
10	Leukomelanoderma syndrome	99.83%	L5	None — rare genetic developmental syndrome	Hold

Notable finding: The most scientifically interesting signal for brigatinib repurposing does not appear in the TxGNN top-10 list but is present in the literature evidence: NF2-related schwannomatosis. A Phase 2 trial published in The New England Journal of Medicine (PMID: 38904277) demonstrated that brigatinib causes tumour shrinkage in NF2-deficient schwannomas and meningiomas through inhibition of multiple tyrosine kinases (not ALK), representing a genuine mechanistically validated repurposing opportunity.

Conclusion and Next Steps

Decision: Hold

Rationale: The top TxGNN-predicted indication (gingival fibromatosis) lacks any mechanistic rationale linking ALK inhibition to the pathophysiology of gingival fibrous overgrowth. There are zero clinical trials and zero publications supporting this specific drug–disease pair. The remaining predictions are similarly unsupported, with the partial exception of anatomical subtypes of NSCLC (lung hilum carcinoma, Pancoast tumour), for which brigatinib’s existing ALK-positive NSCLC indication already applies conditionally. The high TxGNN scores (>99.8%) across all predictions likely reflect the drug’s strong connectivity within the knowledge graph rather than true therapeutic potential for these specific conditions.

To proceed, the following is needed:

Obtain detailed mechanism of action data from DrugBank to assess off-target kinase activity that might be relevant to non-oncologic conditions
Retrieve package insert safety information (key warnings, contraindications) from NPRA to complete the safety profile
Investigate the NF2-schwannomatosis signal further — this represents the most promising repurposing lead supported by Phase 2 clinical evidence (NEJM 2024), though it was not captured in the TxGNN prediction ranking
For lung hilum carcinoma and pulmonary sulcus neoplasm, no additional action is needed — these are anatomical subtypes of NSCLC already covered by the existing ALK-positive NSCLC indication
Consider whether TxGNN model retraining or feature engineering could improve specificity for distinguishing benign from malignant conditions

Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application. Data cutoff: 2026-04-09.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.